Showing 5821-5830 of 8181 results for "".
- New Technology Helps Identify Two Rare Skin Cell Subtypeshttps://practicaldermatology.com/news/20120515-new_technology_helps_identify_two_rare_skin_cell_subtypes/2459799/
- Xeomin Injunction Stands; Another Hearing Scheduled for Tomorrowhttps://practicaldermatology.com/news/20120312-xeomin_injunction_stands_another_hearing_scheduled_for_tomorrow/2459848/Handing down his order as promised on Friday, US District Court Judge Andrew J. Guilford imposed a 10-month injunction barring Merz from selling or soliciting purchases of Xeomin®, in the US facial aesthetics market for 10 months. However, Judge Gui
- FDA Expands Dupixent CSU Indication to Children as Young as 2 Yearshttps://practicaldermatology.com/news/dupixent-approval-expanded-to-include-children-as-young-as-2-years-with-csu/2487479/The US Food and Drug Administration (FDA) has expanded the indication for Dupixent (dupilumab; Sanofi and Regeneron) to include pediatric patients aged 2 to 11 years with chronic spontaneous urticaria (CSU) who remain symptomatic despite H1 antihistamine treatment. The label expansion, according
- SCRATCH-AD: Rapid Itch Reduction, Biomarker Improvements with Ruxolitinibhttps://practicaldermatology.com/news/scratch-ad-rapid-itch-reduction-biomarker-improvements-with-ruxolitinib/2487381/Patients with atopic dermatitis (AD) treated with ruxolitinib 1.5% cream experienced rapid and sustained reductions in itch alongside improvements in disease-associated biomarkers, according to findings from the SCRATCH-AD study. The open-label SCRATCH-AD trial (NCT04839380) evaluated the
- Avapritinib Shows Dermatologic Benefits in Indolent Systemic Mastocytosishttps://practicaldermatology.com/news/avapritinib-shows-dermatologic-benefits-in-indolent-systemic-mastocytosis/2487380/Treatment with avapritinib led to substantial improvements in cutaneous disease manifestations among patients with indolent systemic mastocytosis (ISM), according to results from the phase 2 PIONEER study. Investigators for
- Study: Mineral Sunscreen Whitening Linked to Reduced Application and Protectionhttps://practicaldermatology.com/news/study-links-mineral-sunscreen-whitening-to-reduced-application-and-protection/2487379/New research published in the Journal of Drugs in Dermatology indicates mineral sunscreens produced visible whitening across all skin tones, with a pronounced effect in darker skin tones. Investigators evaluated 5 mi
- Study: JAK Inhibitor–Excimer Laser Combination Improves Repigmentation in Pediatric Vitiligohttps://practicaldermatology.com/news/jak-inhibitorexcimer-laser-combination-improves-repigmentation-in-pediatric-vitiligo-trial/2487301/Children with progressive vitiligo treated with an oral Janus kinase (JAK) inhibitor combined with 308-nm excimer laser therapy experienced significantly greater repigmentation than those treated with topical tacrolimus and excimer laser therapy, according to
- Rubedo Reports Early Clinical Activity for GPX4 Modulator RLS-1496 in Actinic Keratosishttps://practicaldermatology.com/news/rubedo-reports-early-clinical-activity-for-gpx4-modulator-rls-1496-in-actinic-keratosis/2487263/Rubedo Life Sciences announced preliminary findings from a Phase 1b/2a trial evaluating topical RLS-1496 1% cream in adults with actinic keratosis (AK), reporting reductions in lesion counts alongside favorable tolerability data. The interim findings were presented at the RBC Capital Markets Glob
- FDA Approves OTC Switch for Galderma’s Differin Epiduo Acne Gelhttps://practicaldermatology.com/news/fda-approves-otc-switch-for-galdermas-differin-epiduo-acne-gel/2487203/The US Food and Drug Administration (FDA) has approved Galderma’s Differin Epiduo Acne Gel (adapalene 0.1% and benzoyl peroxide 2.5%) for over-the-counter (OTC) use in patients aged 12 years and older, marking a notable prescription-to-OTC transition in acne therap
- Isotretinoin Use in Adolescence Not Linked to Reduced Adult Height: Analysishttps://practicaldermatology.com/news/isotretinoin-use-in-adolescence-not-linked-to-reduced-adult-height-analysis/2487168/Concerns that isotretinoin therapy during adolescence could impair skeletal growth were not supported by findings from a large nationwide Danish study published in